ESF1 Antibody

What is ESF1 and what cellular functions does it perform?

ESF1 (ESF1, Nucleolar Pre-rRNA Processing Protein, Homolog) is a nucleolar protein primarily involved in the early stages of ribosome biogenesis. Research has demonstrated that ESF1 is directly involved in small ribosomal subunit maturation, specifically associating with pre-40S particles. In yeast models, ESF1 knockdown leads to significant decreases in 27SA2 and 20S pre-rRNAs, indicating its critical role in the A2 site cleavage during pre-rRNA processing. Additionally, accumulated evidence suggests ESF1 may play a role in regulating basal transcription and negatively regulates ABT1. The protein consists of 851 amino acids with a molecular weight of approximately 99 kDa, and it interacts with various proteins including UBC, SMURF2, RNF2, SIRT7, SUMO2, and ADAM19 .

What types of ESF1 antibodies are available for research applications?

Several types of ESF1 antibodies are available for research, including polyclonal antibodies directed against various regions of the protein. Most commonly used are rabbit polyclonal antibodies targeting the C-terminal region of human ESF1. These antibodies can be obtained in different conjugated forms, including unconjugated, FITC-conjugated, HRP-conjugated, and biotin-conjugated versions. The available antibodies have been validated primarily for Western blotting applications, with some also suitable for immunofluorescence and ELISA techniques. The antibodies demonstrate varying species reactivity, with many showing predicted reactivity to ESF1 from multiple species including human (100%), dog (79%), horse (79%), pig (86%), rabbit (86%), and rat (86%) .

How does ESF1 contribute to ribosome biogenesis?

ESF1 plays a specific role in the early stages of ribosome biogenesis, particularly in pre-rRNA processing. Research using loss-of-function approaches in human HEK293 cells has demonstrated that ESF1 downregulation significantly alters the pattern of RNA products derived from 47S pre-rRNA. ESF1 associates specifically with pre-40S particles, participating in the small ribosomal subunit maturation pathway. In yeast models, ESF1 knockdown causes dramatic decreases in 27SA2 and 20S pre-rRNAs, along with accumulation of 35S and aberrant 23S pre-ribosomal RNAs. This pattern suggests ESF1 is crucial for A2 site cleavage and may influence A0 and A1 cleavage events. The human ESF1 protein interacts with precursors of small ribosomal subunits and is therefore involved in the early steps of their biogenesis .

What are the optimal conditions for using ESF1 antibodies in Western blotting?

For Western blotting applications with ESF1 antibodies, researchers should establish optimal working dilutions experimentally, as these may vary depending on the specific antibody and sample type. Typically, affinity-purified rabbit polyclonal antibodies against the C-terminal region of ESF1 work effectively for human samples. When preparing samples, cell lysates should be prepared in appropriate buffer systems containing protease inhibitors to prevent degradation of the target protein. For detection, since ESF1 has a molecular weight of approximately 99 kDa, appropriate molecular weight markers should be included. Incubation with primary antibody is typically performed overnight at 4°C in blocking buffer containing 0.09% sodium azide. After washing, incubation with appropriate secondary antibodies (typically anti-rabbit IgG) conjugated to HRP or fluorescent dyes follows. When handling ESF1 antibodies, it's advisable to avoid repeated freeze-thaw cycles by storing in small aliquots at -20°C for long-term storage or at 2-8°C for up to one week for short-term use .

How can I design effective ESF1 knockdown experiments?

For ESF1 knockdown experiments, two primary approaches have proven effective: shRNA-based stable knockdown and siRNA-based transient knockdown. For shRNA stable knockdown, researchers have successfully established knockdown in cell lines such as HEK293 by transducing cells with lentiviral particles encoding ESF1-targeting shRNAs, followed by puromycin selection (10 μg/mL) starting 3 days post-transduction. For siRNA transient knockdown, effective sequences include 5′-CCCAGAAUCGAGUGUUCUA-3′ and 5′-UAGAACACUCGAUUCUGGG-3′. Transfection of siRNAs at working concentrations of 5-15 nM using reagents like Lipofectamine RNAiMAX has shown efficiency in ESF1 knockdown. Knockdown efficiency should be evaluated approximately 36-72 hours post-transfection using both RT-qPCR and Western blotting. For RT-qPCR validation, primer sequences 5′-TGGTAGGACTGCGGACGTAT-3′ and 5′-ATCTCGGGTCCTTTGCAACC-3′ have been successfully employed to amplify ESF1 transcripts .

What immunocytochemistry protocols work best for detecting ESF1 in cell lines?

For effective immunocytochemistry detection of ESF1, cells should be grown on cover slides until reaching appropriate confluence. Fixation in absolute acetone at -20°C for 10 minutes has demonstrated good results in preserving ESF1 localization while maintaining cellular architecture. Following fixation, incubation with rabbit anti-ESF1 antibodies at 1:100 dilution, along with appropriate markers for co-localization studies (such as mouse anti-B23/nucleophosmin or mouse anti-SURF6 at 1:200 dilution) for 1 hour at room temperature allows for specific labeling. After PBS washing (3 × 5 minutes), secondary antibody incubation with Alexa Fluor 568 goat anti-rabbit IgG (for ESF1 detection) and Alexa Fluor 488 goat anti-mouse IgG (for co-localization markers) at appropriate dilutions for 1 hour at room temperature provides strong visualization. When imaging ESF1, particular attention should be paid to its nucleolar localization, which can be confirmed through co-localization with established nucleolar markers .

Why might I observe inconsistent results when using ESF1 antibodies for protein detection?

Inconsistent results with ESF1 antibodies could stem from several factors. First, antibody quality and specificity variations may occur between lots or manufacturers. To address this, validate each new lot using positive controls and consider using recombinant ESF1 as a standard. Second, ESF1 expression levels vary considerably across cell types and tissues, with particularly high expression in rapidly proliferating cells. Therefore, ensure your protein loading is optimized for the specific sample type. Third, inadequate cell lysis or protein extraction can affect ESF1 detection, especially since it is a nucleolar protein. Use stronger lysis buffers containing appropriate detergents to ensure complete extraction of nuclear and nucleolar proteins. Fourth, ESF1 may undergo post-translational modifications that affect antibody recognition. If possible, use multiple antibodies targeting different epitopes to confirm results. Finally, ESF1's large size (99 kDa) can make transfer efficiency variable during Western blotting. Consider extending transfer time or using specialized transfer systems for larger proteins .

How can I distinguish between ESF1's roles in pre-rRNA processing versus potential roles in transcriptional regulation?

Distinguishing between ESF1's roles in pre-rRNA processing and transcriptional regulation requires multi-faceted experimental approaches. First, perform RNA immunoprecipitation (RIP) assays using ESF1 antibodies to identify directly associated RNA species, focusing on both pre-rRNAs and mRNAs. Compare the enrichment profiles to distinguish predominant associations. Second, implement quantitative Northern blot analysis after ESF1 knockdown to examine specific pre-rRNA intermediates (particularly 35S, 27SA2, 27SB, and 20S pre-rRNAs) to assess processing defects. Third, use ChIP-seq with ESF1 antibodies to identify potential DNA binding sites that would suggest direct transcriptional regulatory activity. Fourth, perform RNA-seq after ESF1 depletion, distinguishing between immediate early effects (likely direct) and later effects (potentially indirect). Finally, conduct biochemical fractionation studies to determine ESF1's distribution between chromatin-associated, nucleoplasmic, and nucleolar fractions. The combined data from these approaches will help differentiate between ESF1's direct roles in pre-rRNA processing versus potential transcriptional regulatory functions .

What advanced techniques can I use to study ESF1's protein interaction network?

To comprehensively map ESF1's protein interaction network, several advanced techniques can be employed. First, proximity-dependent biotin identification (BioID) or APEX approaches can identify proteins in close proximity to ESF1 in living cells. This involves generating ESF1 fusion constructs with promiscuous biotin ligases, followed by streptavidin pulldown and mass spectrometry. Second, co-immunoprecipitation coupled with mass spectrometry (Co-IP-MS) using ESF1 antibodies can identify stable interaction partners. Consider both native conditions and crosslinking approaches to capture transient interactions. Third, yeast two-hybrid screening or mammalian two-hybrid systems can identify direct binary interactions. Fourth, fluorescence resonance energy transfer (FRET) or bimolecular fluorescence complementation (BiFC) can validate specific interactions in live cells. Finally, in silico approaches using tools like STRING database can help predict functional associations. Current data indicates ESF1 interactions with UBC, SMURF2, RNF2, SIRT7, SUMO2, and ADAM19, suggesting roles beyond ribosome biogenesis in regulatory networks that warrant further investigation .

What is the significance of ESF1 in cancer research, particularly in ER+ breast cancer?

ESF1 has emerged as a significant factor in cancer research, particularly in estrogen receptor-positive (ER+) breast cancer, which accounts for approximately two-thirds of all breast cancers. Proteomic analysis using isobaric tags for relative and absolute quantitation (iTRAQ) has identified ESF1 as significantly upregulated in ER+ breast cancer tissues compared to adjacent normal tissues. Functional studies have demonstrated that ESF1 acts as a hub gene in breast cancer networks, with knockdown experiments showing significant inhibition of cancer cell proliferation. Specifically, ESF1 knockdown inhibits colony formation, increases cell apoptosis, and reduces wound healing capacity in breast cancer cell models. Clinical significance is underscored by the finding that ESF1 expression levels negatively correlate with patient prognosis, suggesting higher expression is associated with poorer outcomes. These findings position ESF1 as a potential novel target for therapeutic development in ER+ breast cancer, highlighting the importance of antibody-based techniques for studying its expression and function in cancer contexts .

How does ESF1 function differ between normal cells and cancer cells?

ESF1 exhibits distinct functional patterns between normal cells and cancer cells, particularly in relation to ribosome biogenesis and cellular proliferation. In normal cells, ESF1 primarily functions in the regulated process of pre-rRNA processing, specifically in the maturation of 40S ribosomal subunits through its involvement in pre-rRNA cleavage at specific sites. This process occurs at baseline levels to maintain normal cellular protein synthesis capacity. In contrast, cancer cells frequently display upregulated ESF1 expression, as demonstrated in proteomic analyses of ER+ breast cancer tissues. This upregulation appears to promote increased ribosome biogenesis, supporting the elevated protein synthesis demands of rapidly proliferating cancer cells. Functionally, ESF1 in cancer cells contributes to enhanced proliferative capacity, as evidenced by reduced colony formation and increased apoptosis following ESF1 knockdown. Additionally, ESF1 in cancer cells appears to promote cell migration, with knockdown experiments showing inhibited wound healing capacity. These differential activities suggest ESF1 may be co-opted in malignant transformation to support both the biosynthetic and migratory requirements of cancer cells, representing a potential vulnerability that could be exploited therapeutically .

What potential therapeutic strategies could target ESF1 in disease contexts?

Potential therapeutic strategies targeting ESF1 in disease contexts, particularly in cancers where it is upregulated, could follow several approaches. First, RNA interference-based therapeutics using siRNA or shRNA delivery systems targeting ESF1 mRNA could reduce its expression. Successful sequences for this approach have been identified, including 5′-CCCAGAAUCGAGUGUUCUA-3′ and 5′-UAGAACACUCGAUUCUGGG-3′, which have demonstrated efficacy in reducing ESF1 expression in cellular models. Second, small molecule inhibitors designed to disrupt ESF1's function in pre-rRNA processing could be developed through high-throughput screening approaches. Given ESF1's role in ribosome biogenesis, such inhibitors might preferentially affect rapidly proliferating cells with high protein synthesis demands, potentially offering selectivity for cancer cells. Third, peptide-based approaches using competitive inhibitors of ESF1's protein-protein interactions could disrupt its functional networks. Fourth, antibody-drug conjugates utilizing ESF1 antibodies could deliver cytotoxic payloads specifically to cells overexpressing ESF1. Finally, PROTAC (Proteolysis-targeting chimera) technology could be employed to target ESF1 for degradation. The development of these strategies requires detailed understanding of ESF1's structure-function relationships and its context-specific roles in normal and disease states .

How can I accurately quantify ESF1 expression across different experimental conditions?

Accurate quantification of ESF1 expression across experimental conditions requires multiple complementary approaches. For protein-level quantification, Western blotting with ESF1-specific antibodies provides a reliable method when coupled with appropriate loading controls and densitometry analysis. For enhanced precision, consider using the Li-Cor Odyssey system or similar fluorescence-based quantification platforms rather than chemiluminescence. At the mRNA level, RT-qPCR using validated primers (5′-TGGTAGGACTGCGGACGTAT-3′ and 5′-ATCTCGGGTCCTTTGCAACC-3′) allows for sensitive quantification when normalized to stable reference genes. For high-throughput approaches, RNA-seq or proteomic analyses provide broader context for ESF1 expression changes. When comparing across cell types or tissues, account for baseline differences in ESF1 expression by using relative fold changes rather than absolute values. Finally, to verify the specificity of antibody-based detection methods, always include appropriate controls including ESF1 knockdown samples. This multi-modal approach ensures robust quantification of ESF1 expression changes in response to experimental manipulations .

What control experiments should be included when studying ESF1 function using antibody-based techniques?

When studying ESF1 function using antibody-based techniques, several essential control experiments should be included to ensure valid interpretations. First, antibody specificity controls should include Western blot analysis of samples from ESF1 knockdown cells alongside wild-type cells to confirm the specificity of the observed band. Second, for immunofluorescence experiments, peptide competition assays where the antibody is pre-incubated with the immunizing peptide should be performed to verify specific staining. Third, isotype controls using non-specific immunoglobulins of the same species and class as the ESF1 antibody should be included in all staining protocols. Fourth, when performing immunoprecipitation, both "no-antibody" and "irrelevant antibody" controls are necessary to distinguish specific from non-specific pulldowns. Fifth, for functional studies involving ESF1 knockdown, rescue experiments reintroducing ESF1 expression should be conducted to confirm that observed phenotypes are specifically due to ESF1 depletion rather than off-target effects. Finally, when studying ESF1 in disease contexts, appropriate normal tissue or cell controls must be included that match the pathological samples in terms of tissue origin, processing methods, and analysis techniques .